NBIX Neurocrine Biosciences, Inc. - Fundamental Analysis
NEUTRAL
Sign in to save
Save this symbol to a watchlist or track a position.
NBIX Stock | Fundamental Analysis & Investment Insights
NASDAQ
Healthcare
Drug Manufacturers - Specialty & Generic
Current Price
Live
$132.39
Analyst Target
$179.59
+35.7%
Upside
52W High
$160.18
52W Low
$84.23
At a glance
Key valuation, profitability, growth, and risk metrics.
AI Analysis
Powered by advanced machine learning algorithms
Confidence Score
72%
Analysis Accuracy
Neurocrine Biosciences has a weak Piotroski F-Score of 4/9, indicating marginal financial health, and lacks an Altman Z-Score for distress risk assessment. Despite strong profitability and robust revenue and earnings growth, the stock trades above its Graham Number of $53.29 at $132.39, reflecting high market expectations. While analysts maintain a strong_buy recommendation with a target of $179.59, insider selling activity and inconsistent earnings beats over the past year suggest caution. The company's solid balance sheet and low leverage provide resilience, but valuation and sentiment signals are mixed.
Key Strengths
Strong revenue growth (27.8% YoY) outpacing sector average of 9.8%
High operating margin (30.10%) and gross margin (63.21%) indicating pricing power and cost efficiency
Low debt/equity ratio of 0.16, well below sector average of 0.92, signaling conservative capital structure
Healthy liquidity with current ratio of 3.38 and quick ratio of 2.89
Analyst consensus is strong_buy with high target price of $179.59, implying 35.6% upside
Key Risks
Piotroski F-Score of 4/9 indicates weak to stable financial health, limiting confidence in operational consistency
Insider selling activity: $23.21M in sales over last 6 months with no buys, signaling bearish sentiment from insiders
Stock trades at a significant premium to Graham Number ($53.29) — current price is 148% higher
Earnings surprise history is volatile, with 2 misses in last 4 quarters and an average negative surprise of -7.16% over that period
Forward P/E of 14.48 is reasonable, but current P/E of 31.60 is elevated relative to earnings stability
AI Fair Value Estimate
Based on comprehensive analysis
$123.61
-6.6% below current price
Performance Snowflake
Multi-dimensional AI analysis across 5 key categories
Stock Price & Analyst Targets
Real-time price movements and analyst price targets
Historical Performance Trends
Long-term financial metrics and growth patterns
Valuation Metrics
Key valuation ratios and pricing indicators
Profitability, Growth & Financial Health
Detailed profit margins, ROE, debt ratios, and liquidity metrics
Sector Comparison & Peer Analysis
Compare NBIX against industry averages and similar companies
Insider Trading & Analyst Ratings
Track insider transactions and Wall Street analyst recommendations
Past News Coverage
Recent headlines mentioning NBIX from our newsroom.
Newest → oldest
No matching news yet.